Biospecifics Technologies (BSTC) Growth Rates Comparisons to Major Pharmaceutical Preparations Industry, Sector, Market. Sales, Income, EPS
CSIMarket Company Name, Ticker, Customers, else..
 
Biospecifics Technologies Corp  (NASDAQ: BSTC)
 

Biospecifics Technologies Growth Comparisons

Select each growth Category to receive further Information




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

BSTC Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q3 MRQ) 19.21 % 16.43 % 10.98 % -2.03 %
Q / Q Revenue Growth (Q3 MRQ) 188.36 % 10.18 % 15.57 % 13.28 %
Y / Y Revenue Growth (for 12 months ending Q3 TTM) -1.19 % 13.12 % 6.95 % -3.2 %
Sequential Revenue Growth (for 12 months ending Q3 TTM) 5.21 % 3.34 % 2.33 % -0.52 %
Revenue 5 Year Average Growth 22.09 % 13.71 % 9.82 % 10.45 %


BSTC's Growth Comparisons in III. Quarter 2020




Biospecifics Technologies improved it's Revenue by 19.21% year on year in the third quarter 2020, and outpaced the 16.43% rise in the Major Pharmaceutical Preparations industry, and 10.98% improvement in the Healthcare sector. Above the average sales gains in the Healthcare and in the Major Pharmaceutical Preparations industry, helped to elevate overall market growth to -2.03%.

Company's sequential Revenue growth rate was impressive 188.36% from the second quarter. Average yearly sales growth for Biospecifics Technologies is 22.09%, while S & P 500's average annual sales growth is 10.45% over the five years, including only Businesses with the third quarter 2020 financial reports.


Growth Rates of BSTC's Income in the third quarter 2020


BSTC Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q3 MRQ) -11.05 % -33.59 % -4.59 % -6.93 %
Sequential Operating Income Change (Q3 MRQ) - 44.13 % 64.95 % 61.86 %
Y / Y Operating Income Growth (Q3 TTM) -23.02 % -6.34 % 41.59 % -9.34 %
Sequential Operating Income Growth (Q3 TTM) -3.81 % -12.01 % -1.37 % -3.15 %
Operating Income 5 Year Avg. Change 32.25 % 10 % -0 % 12.37 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q3 MRQ) -14.13 % -17.84 % 5.77 % -12.84 %
Sequential Income from Cont. Ops. Change (Q3 MRQ) 4551.81 % 34.31 % 72.61 % 108.36 %
Y / Y Income from Cont. Ops. Change (Q3 TTM) -25.51 % -0.66 % 1.15 % -29.54 %
Sequential Income from Cont. Ops. Change (Q3 TTM) -4.86 % -4.3 % 2.99 % -3.86 %
Income from Cont. Ops. 5 Year Avg. Change 39.42 % 31.87 % 20.95 % 12.23 %

BSTC Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q3 MRQ) -14.13 % -17.89 % 5.77 % -10.3 %
Q / Q Net Income Growth (Q3 MRQ) 4551.81 % 33.98 % 80.49 % 113.34 %
Y / Y Net Income Change (Q3 TTM) -27.22 % -8.23 % -2.96 % -30.13 %
Sequential Net Income Change (Q3 TTM) -4.86 % -4.23 % 3.42 % -3.08 %
Net Income 5 Year Avg. Growth 39.42 % 7.44 % 5.09 % 11.73 %

BSTC's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q3 MRQ) -15.12 % -24.73 % 5.77 % -12.84 %
Sequential EPS from Cont. Ops. Change (Q3 MRQ) 3550 % 29.49 % 72.61 % 108.36 %
Y / Y EPS from Cont. Ops. Change (Q3 TTM) -25.94 % - - -
Sequential EPS from Cont. Ops. Change (Q3 TTM) -5.2 % - - 1.84 %
EPS from Cont. Ops. 5 Year Avg. Growth 36 % 16.65 % 20.95 % 12.23 %



BSTC EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q3 MRQ) -14.12 % -24.77 % 5.77 % -10.3 %
Q / Q EPS Net Growth (Q3 MRQ) 3550 % 29.18 % 80.49 % 113.34 %
Y / Y EPS Net Change (for 12 months ending Q3 TTM) - - - -43.72 %
Sequential EPS Net Change (for 12 months ending Q3 TTM) -4.84 % - - 1.1 %
EPS Net 5 Year Avg. Change 38.22 % 7.44 % 5.09 % 11.73 %



Biospecifics Technologies saw it's income per share fall by -14.12% from the same quarter a year ago, in the third quarter, Biospecifics Technologies was still better off than the Major Pharmaceutical Preparations industry reporting -24.77% but underperformed the 5.77% EPS growth in the Healthcare sector. Healthcare sector grew above the market average, while the Major Pharmaceutical Preparations industry and Biospecifics Technologies Corp results underperformed, in the third quarter 2020.

The Company's sequential EPS growth rate was very impressive 3550% from the second quarter. Average yearly income per share growth for Biospecifics Technologies is 38.22%, while S & P 500's average annual income per share growth is 11.73% over the five years, including only Businesses with the third quarter 2020 earnings results.

BSTC Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q3 MRQ) -65.66 % -5.37 % 5.83 % -36.86 %
Sequential Free Cash Flow Change (Q3 MRQ) -75.53 % 7.8 % -5.46 % -38.08 %
Y / Y Free Cash Flow Change (Q3 TTM) 20.63 % 17.24 % 22.38 % -6.79 %
Sequential Free Cash Flow Change (Q3 TTM) -11.36 % -2.38 % 1.48 % -7.65 %
Free Cash Flow 5 Year Avg. Change 29.45 % 13.99 % 9.38 % 17.08 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q3 MRQ) - -30.77 % -44.36 % -
Sequential Net Cash Flow Change (Q3 MRQ) - - 187.59 % -
Y / Y Net Cash Flow Change (Q3 TTM) - -58.61 % 65.43 % -
Sequential Net Cash Flow Change (Q3 TTM) - -29.44 % -21.68 % -7.66 %
Net Cash Flow 5 Year Avg. Change - - 65.81 % 280.55 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q3 MRQ) - 13.27 % 2.34 % -16.87 %
Sequential Capital Expenditures Change (Q3 MRQ) - 20.91 % 19.42 % 0.59 %
Y / Y Capital Expenditures Change (Q3 TTM) - 8.68 % -6.91 % -15.27 %
Sequential Capital Expenditures Change (Q3 TTM) 0 % 4.17 % 0.9 % -4.51 %
Capital Expenditures 5 Year Avg. Change - 8.04 % 9.26 % 6.87 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Y/Y Annual




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.